Percutaneous hepatic perfusion
||This article includes a list of references, related reading or external links, but its sources remain unclear because it lacks inline citations. (October 2015) (Learn how and when to remove this template message)|
Percutaneous hepatic perfusion (PHP) is a regionalized, minimally-invasive approach to cancer treatment currently undergoing Phase II and Phase III clinical testing. PHP treats a variety of hepatic tumors by isolating the liver and exposing the organ to high-dose chemotherapy. As demonstrated in clinical trials, patients treated by PHP can tolerate much higher doses of chemotherapeutic agents than those receiving traditional systemic chemotherapy without increased toxicities.
Using a system of catheters and filters, PHP isolates the liver from the circulatory system and infuses a chemotherapeutic agent directly to the liver via the hepatic artery. The venous effluent from the liver is then filtered outside of the body and the filtered blood is returned into the jugular vein. PHP is a repeatable procedure and can be performed in an operating room or a radiology suite under local or general anesthesia.
- Business Wire
- Delcath Systems, Inc.
- Pingpank JF, Libutti SK, Chang R, et al. (May 2005). "Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies". J. Clin. Oncol. 23 (15): 3465–74. PMC . PMID 15908655. doi:10.1200/JCO.2005.00.927.
- Seidel GD, Locklin J, Muehlbauer PM (June 2006). "Part I: regional chematherapy clinical studies in nontraditional clinical settings". Clin J Oncol Nurs. 10 (3): 338–44. PMID 16789579. doi:10.1188/06.CJON.338-344.
|This oncology article is a stub. You can help Wikipedia by expanding it.|